[{"id":"c8b861fe-9535-4dcc-814c-0f3b487628c9","acronym":"FX-909-CLINPRO-1","url":"https://clinicaltrials.gov/study/NCT05929235","created_at":"2023-07-03T16:10:43.192Z","updated_at":"2024-07-02T16:34:59.877Z","phase":"Phase 1","brief_title":"A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma","source_id_and_acronym":"NCT05929235 - FX-909-CLINPRO-1","lead_sponsor":"Flare Therapeutics Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FX-909"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 08/24/2023","start_date":" 08/24/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 01/30/2027","study_completion_date":" 01/30/2027","last_update_posted":"2024-05-31"}]